<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396161</url>
  </required_header>
  <id_info>
    <org_study_id>B1731007</org_study_id>
    <nct_id>NCT01396161</nct_id>
  </id_info>
  <brief_title>A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients</brief_title>
  <official_title>A Phase 1 Placebo-controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Oral Doses Of Pf-05175157 In Healthy Volunteers And In Patients With Type 2 Diabetes Mellitus (t2dm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics
      and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and
      patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to PF-05175157 was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for Area Under the Concentration-Time Curve (Rˇac, AUC)</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
    <description>Rˇac for the AUC is defined as AUC (τ, single dose [ss]) / AUC (τ, multiple dose [sd]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr)</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
    <description>CLr is the amount of unchanged drug excreted in the participants urine from time zero to end of dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Recovery</measure>
    <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
    <description>Percentage of PF-05175157 excreted unchanged in urine over the dosing interval.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>30 mg PF-05175157 or Placebo QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PF-05175157 or Placebo QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose might be modified based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg PF-05175157 or Placebo QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose might be modified based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PF-05175157 or Placebo BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Planned dose might be modified based on emerging safety and PK data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>xxx mg PF-05175157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose will be determined based on results obtained from Arms 1 to 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.</description>
    <arm_group_label>30 mg PF-05175157 or Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.</description>
    <arm_group_label>100 mg PF-05175157 or Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.</description>
    <arm_group_label>200 mg PF-05175157 or Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.</description>
    <arm_group_label>100 mg PF-05175157 or Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.</description>
    <arm_group_label>xxx mg PF-05175157</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
             Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests.

          -  In addition, subjects must have normal pulmonary function tests and normal ocular
             examination.

          -  Body Mass Index (BMI) of 25.5 - 35.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Women must be of non-childbearing potential.

          -  Subjects with type 2 diabetes: HbA1c ≥7.0% and ≤10.0% if on metformin only, and ≥6.5%
             and ≤9.0% if patient requires to be washed-off an SU or DPP-4i.

          -  For subjects with type 2 diabetes, due to possible effects on disposition, CYP P450
             3A4/5 and 2D6 substrates should not be co-administered with study medications.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
             disease (including drug allergies, but excluding untreated, asymptomatic seasonal
             allergies at time of dosing).

          -  Evidence or history of any chronic ongoing or current pulmonary disease.

          -  History of smoking in the past 5 years and a history of smoking more than 10 pack
             years, or history or evidence of habitual use of other (non smoked) tobacco or
             nicotine containing products within 3 months of Screening, or positive cotinine test
             at Screening or Day -3.

          -  Active ocular disease including infection, glaucoma, seasonal allergies, dry eye
             symptoms or retinal/optic nerve disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRA Clinical Research</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Physicians of South Florida</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731007&amp;StudyName=A%20Study%20of%20PF-05175157%20in%20Healthy%20Volunteers%20and%20Type%202%20Diabetic%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <results_first_submitted>April 1, 2016</results_first_submitted>
  <results_first_submitted_qc>September 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2016</results_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Multiple Doses</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Type 2 Diabetic Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Healthy and Overweight Participants (HOV)</title>
          <description>HOV participants administered orally matched placebo capsules once daily (QD) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Type 2 Diabetes Mellitus Participants (T2DM)</title>
          <description>T2DM participants administered orally matched placebo capsules QD for 14 days</description>
        </group>
        <group group_id="P3">
          <title>PF-05175157 30 mg QD - HOV</title>
          <description>HOV participants administered orally 30 milligram (mg) capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="P4">
          <title>PF-05175157 100 mg QD - HOV</title>
          <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="P5">
          <title>PF-05175157 200 mg QD - HOV</title>
          <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="P6">
          <title>PF-05175157 100 mg BID - HOV</title>
          <description>HOV participants administered orally 100 mg capsules of PF-05175157 twice daily (BID) for 14 days</description>
        </group>
        <group group_id="P7">
          <title>PF-05175157 200 mg QD - T2DM</title>
          <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - HOV</title>
          <description>HOV participants administered orally matched placebo capsules QD for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo - T2DM</title>
          <description>T2DM participants administered orally matched placebo capsules QD for 14 days</description>
        </group>
        <group group_id="B3">
          <title>PF-05175157 30 mg QD - HOV</title>
          <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="B4">
          <title>PF-05175157 100 mg QD -HOV</title>
          <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="B5">
          <title>PF-05175157 200 mg QD - HOV</title>
          <description>HOV participants administered orally 200 mg capsules PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="B6">
          <title>PF-05175157 100 mg BID - HOV</title>
          <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
        </group>
        <group group_id="B7">
          <title>PF-05175157 200 mg QD - T2DM</title>
          <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="11"/>
            <count group_id="B8" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to PF-05175157 was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.</description>
        <time_frame>2 weeks</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication (PF-05175157 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - HOV</title>
            <description>HOV participants administered orally matched placebo capsules QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo - T2DM</title>
            <description>T2DM participants administered orally matched placebo capsules QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O6">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O7">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to PF-05175157 was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication (PF-05175157 or placebo).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>Pharmacokinetic Concentration (PKC) Analysis Population: all enrolled participants who received at least 1 dose of PF-05175157 and had at least 1 concentration value reported. Number of Participants Analyzed (N): number of participants with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>Pharmacokinetic Concentration (PKC) Analysis Population: all enrolled participants who received at least 1 dose of PF-05175157 and had at least 1 concentration value reported. Number of Participants Analyzed (N): number of participants with evaluable data</population>
          <units>micrograms per milliliter (µg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="0.28"/>
                    <measurement group_id="O2" value="7.52" spread="2.87"/>
                    <measurement group_id="O3" value="21.75" spread="4.44"/>
                    <measurement group_id="O4" value="15.18" spread="2.11"/>
                    <measurement group_id="O5" value="23.26" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>Pharmacokinetic Parameter (PKP) Analysis Population: all enrolled participante who received at least 1 dose of PF05175157 and had at least 1 PKP of interest calculated;Number of Participants Analyzed (N): number of participants with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>Pharmacokinetic Parameter (PKP) Analysis Population: all enrolled participante who received at least 1 dose of PF05175157 and had at least 1 PKP of interest calculated;Number of Participants Analyzed (N): number of participants with evaluable data</population>
          <units>hours (hrs)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)</title>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)</title>
          <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
          <units>µg times (*)hr divided by mL (µg *hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.86" spread="4.01"/>
                    <measurement group_id="O2" value="90.50" spread="33.40"/>
                    <measurement group_id="O3" value="255.9" spread="36.98"/>
                    <measurement group_id="O4" value="125.6" spread="16.73"/>
                    <measurement group_id="O5" value="282.6" spread="66.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio for Area Under the Concentration-Time Curve (Rˇac, AUC)</title>
        <description>Rˇac for the AUC is defined as AUC (τ, single dose [ss]) / AUC (τ, multiple dose [sd]).</description>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for Area Under the Concentration-Time Curve (Rˇac, AUC)</title>
          <description>Rˇac for the AUC is defined as AUC (τ, single dose [ss]) / AUC (τ, multiple dose [sd]).</description>
          <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.11"/>
                    <measurement group_id="O2" value="1.01" spread="0.34"/>
                    <measurement group_id="O3" value="1.47" spread="0.22"/>
                    <measurement group_id="O4" value="2.53" spread="0.76"/>
                    <measurement group_id="O5" value="1.54" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr)</title>
        <description>CLr is the amount of unchanged drug excreted in the participants urine from time zero to end of dosing interval.</description>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr)</title>
          <description>CLr is the amount of unchanged drug excreted in the participants urine from time zero to end of dosing interval.</description>
          <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="1.25"/>
                    <measurement group_id="O2" value="5.30" spread="1.42"/>
                    <measurement group_id="O3" value="4.57" spread="1.83"/>
                    <measurement group_id="O4" value="5.93" spread="1.86"/>
                    <measurement group_id="O5" value="5.42" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>It was not possible to calculate data for half-life as the calculation required the slope of terminal elimination phase and the PK sampling was insufficient to characterize the terminal elimination phase, which is needed for the calculation of the half-life.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - HOV</title>
            <description>HOV participants administered orally matched placebo capsules QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo - T2DM</title>
            <description>T2DM participants administered orally matched placebo capsules QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O6">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O7">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>It was not possible to calculate data for half-life as the calculation required the slope of terminal elimination phase and the PK sampling was insufficient to characterize the terminal elimination phase, which is needed for the calculation of the half-life.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Recovery</title>
        <description>Percentage of PF-05175157 excreted unchanged in urine over the dosing interval.</description>
        <time_frame>Hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Day 1 and 14; at Hour 0 (pre-dose), 3.5, 12 hours post-dose for Day 4, 7 and 11</time_frame>
        <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 30 mg QD - HOV</title>
            <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 100 mg QD - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PF-05175157 200 mg QD - HOV</title>
            <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
          <group group_id="O4">
            <title>PF-05175157 100 mg BID - HOV</title>
            <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
          </group>
          <group group_id="O5">
            <title>PF-05175157 200 mg QD - T2DM</title>
            <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Recovery</title>
          <description>Percentage of PF-05175157 excreted unchanged in urine over the dosing interval.</description>
          <population>PKP analysis population; Participants Analyzed (N): number of participants with evaluable data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.59" spread="7.78"/>
                    <measurement group_id="O2" value="27.30" spread="8.14"/>
                    <measurement group_id="O3" value="33.75" spread="9.53"/>
                    <measurement group_id="O4" value="43.60" spread="10.72"/>
                    <measurement group_id="O5" value="44.31" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - HOV</title>
          <description>HOV participants administered orally matched placebo capsules QD for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo - T2DM</title>
          <description>T2DM participants administered orally matched placebo capsules QD for 14 days</description>
        </group>
        <group group_id="E3">
          <title>PF-05175157 30 mg QD - HOV</title>
          <description>HOV participants administered orally 30 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="E4">
          <title>PF-05175157 100 mg QD - HOV</title>
          <description>HOV participants administered orally 100 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="E5">
          <title>PF-05175157 200 mg QD - HOV</title>
          <description>HOV participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
        <group group_id="E6">
          <title>PF-05175157 100 mg BID - HOV</title>
          <description>HOV participants administered orally 100 mg capsules of PF-05175157 BID for 14 days</description>
        </group>
        <group group_id="E7">
          <title>PF-05175157 200 mg QD - T2DM</title>
          <description>T2DM participants administered orally 200 mg capsules of PF-05175157 QD for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

